Help the Future of Cancer Treatment

Volunteering for a clinical trial is a contribution to the future of medicine that only you can make.

Testing effectiveness of navigation interventions to increase uptake of cascade genetic testing among relatives of individuals diagnosed with hereditary cancer syndromes

Primary Investigator
Stoffel, Elena
Status
OPEN TO ACCRUAL
Phase
NA
NCT Number
NCT06927947
UM Number
2024.087
Age Group
Adults
Management Group
CTSU - Oncology
Oncology Group
Cancer Control and Prevention
ID (Protocol)
57962
Secondary Protocol No
HUM00257832
Scope
Unspecified
Sponsor Type
National
Disease Site
Anus
Bones and Joints
Brain and Nervous System
Breast
Cervix
Colon
Corpus Uteri
Esophagus
Eye and Orbit
Hodgkin's Lymphoma
Ill-Defined Sites
Kaposi's Sarcoma
Kidney
Larynx
Leukemia, other
Lip, Oral Cavity and Pharynx
Liver
Lung
Lymphoid Leukemia
Melanoma, Skin
Multiple Myeloma
Mycosis Fungoides
Myeloid and Monocytic Leukemia
Non-Hodgkin's Lymphoma
Other Digestive Organ
Other Endocrine System
Other Female Genital
Other Hematopoietic
Other Male Genital
Other Respiratory and Intrathoracic Organs
Other Skin
Other Urinary
Ovary
Pancreas
Prostate
Rectum
Small Intestine
Soft Tissue
Stomach
Thyroid
Unknown Sites
Urinary Bladder
Summary
This clinical trial tests whether various web-based tools can help improve communication about hereditary cancer risk in families and decrease barriers to genetic testing for relatives of patients with hereditary cancer syndromes. Between 5% and 10% of all cancers are caused by genetic changes that are hereditary, which means that they run in families. Some kinds of cancer or certain cancers diagnosed in biological relatives may mean patients are more likely to have a genetic change. Once a genetic change is identified in a family, other biological relatives can choose to undergo testing themselves to better understand their cancer risk. The uptake of genetic testing in other biological relatives once a genetic condition is identified is about 20% to 30%. The Cascade Genetic Testing Platform is a virtual tool that seeks to overcome barriers related to logistics of family communication and improve dissemination of genetic testing information which is clinically actionable for individuals at highest risk for cancer. Using the Cascade Genetic Testing Platform may improve ways to share information about hereditary risk with biological relatives.

Eligibility: Inclusion Criteria
  •   * PROBANDS: Clinically confirmed autosomal dominant pathogenic germline variant (PGV) associated with a hereditary cancer syndrome
  •   * PROBANDS: Previous evaluation by the University of Michigan (U-M) Cancer Genetics Clinic
  •   * PROBANDS: >= 18 years old
  •   * PROBANDS: Able to speak and read English
  •   * PROBANDS: Access to the internet
  •   * RELATIVES: Biological relative of proband
  •   * RELATIVES: >= 18 years old
  •   * RELATIVES: Able to speak and read English
  •   * RELATIVES: Access to the internet
  •   * RELATIVES: Have not completed germline genetic testing, per self-report at baseline
Exclusion Criteria
  •   * RELATIVES: Prior clinical germline genetic testing for cancer or already have an upcoming appointment scheduled with a genetics provider, per self-report at baseline